Filing Flows › Xilio Therapeutics (XLO) › Q1 2025
Xilio Therapeutics (XLO) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Xilio Therapeutics (XLO) reported revenue of $2.9M for the first quarter 2025 (Q1 2025) and +70% from the quarter before. Operating margin was -472.7%, net loss $13.3M (452.7% of revenue).
Xilio Therapeutics, Q1 2025: revenue $2.9M, operating margin -472.7%, net loss $13.3M, operating cash flow $29.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.9M | +70% | — |
| Operating profit | −$13.9M | — | — |
| Net earnings | −$13.3M | — | — |
| Operating cash flow | $29.0M | — | — |
| Free cash flow | $29.0M | — | — |
What changed
Revenue was $2.9M in Q1 2025, up 70% from the previous quarter.
Operating costs exceeded revenue by $13.9M, an operating margin of -472.7%. The quarter ended with a net loss of $13.3M, wider than the previous quarter's $13.1M loss.
Operating cash flow was $29.0M. Non-cash charges added back $497K of depreciation and amortization and $1.5M of share-based compensation. Working capital and other items added $40.2M. Capital expenditures of $22K left free cash flow of $29.0M.
Questions
What was Xilio Therapeutics' revenue in the first quarter 2025?
Xilio Therapeutics (XLO) reported revenue of $2.9M for the first quarter 2025 (Q1 2025) and +70% from the quarter before.
Was Xilio Therapeutics profitable in the first quarter 2025?
Operating loss was $13.9M (-472.7% of revenue) and net loss $13.3M.
Source: Xilio Therapeutics 10-Q on SEC EDGAR.